NAD+ for Health & Longevity - Quick Reference Sheet

NAD+ for Health & Longevity

Created on 10/15/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Gemini 4 Argon – Audit

Nicotinamide adenine dinucleotide (NAD+) is a cellular helper molecule administered by intravenous infusion, injection, or oral supplement to support cellular energy, genetic repair, and longevity. Human evidence for direct NAD+ has low certainty: hospital add-on trials show mixed heart failure results and faster hearing recovery, while most endurance and cognition studies tested vitamin B3 forms. High-dose infusions require slow administration over hours to prevent acute cramping and nausea. (Full Review)

Protocol

Low-dose cardiovascular protocol
10–50 mg/day intravenous for 7 days
10 mg/day in 100 mL glucose or saline over 40–60 minutes, or 50 mg/day in 50 mL saline (0.9% normal saline for diabetic protocols)
High-dose wellness infusion protocol
500–750 mg/day intravenous
500 mg/day for 4 days or 750 mg infused slowly over 6 hours (3 μmol/min) in the morning or early afternoon
Intramuscular, subcutaneous, and oral regimens
50–100 mg subcutaneous, 5 mg intramuscular, or 10–20 mg oral NADH
Subcutaneous 50–100 mg split 1–3× weekly; intramuscular 5 mg/day; oral NADH 10–20 mg/day as a single morning dose
Time to effect
Hearing Recovery in Sudden Sensorineural Hearing Loss
62.97 days
Mean hearing recovery time with intramuscular NAD+ (113.01 days shorter than 175.98 days in control; +34.44% recovery rate, +17.15 decibels hearing level gain)
Cognitive Function and Neuroprotection
4–12 weeks
Oral NADH cognitive response (standardized mean difference 1.50 for global cognitive performance vs. control; memory and attention unchanged)
Left Ventricular Function in Heart Failure
4 weeks
1-month left ventricular ejection fraction (LVEF) improvement (+2.24 percentage points vs. placebo) after a 7-day intravenous course

Benefits

Contraindications
  • Active malignancy, lymphoma, or precancerous lesions
  • Severe hepatic impairment or cirrhosis (liver enzymes AST or ALT > 3× upper limit of normal)
  • Severe renal dysfunction (serum creatinine ≥ 225 μmol/L [~2.55 mg/dL])
  • Uncontrolled hypertension (systolic blood pressure ≥ 180 mmHg and/or diastolic ≥ 110 mmHg)
  • Decompensated heart failure or unstable cardiovascular disease (New York Heart Association [NYHA] Class IV heart failure, acute coronary syndrome, malignant arrhythmias, pulmonary embolism)
  • Pregnancy and lactation
Key Interactions
  • Antihypertensives and vasodilators (lisinopril, losartan, amlodipine, sildenafil): Caution (theoretical)
  • Antidiabetic medications and insulin (metformin, glipizide, insulin glargine): Monitor (with 5% glucose diluent)
  • PARP-inhibitor oncology drugs (olaparib, rucaparib, niraparib): Avoid (theoretical)
  • Over-the-counter analgesics and anti-inflammatories (acetaminophen, ibuprofen, naproxen): Monitor (theoretical)
  • Vitamin B3 precursors and NAD+ boosters (nicotinamide riboside, nicotinamide mononucleotide, niacin, nicotinamide): Caution (theoretical)
  • CD38-inhibiting flavonoids and metabolic cofactors (quercetin, apigenin, coenzyme Q10): Monitor (theoretical for CD38 inhibitors)
  • Methyl-group donors (trimethylglycine [betaine], S-adenosylmethionine, methylfolate, methylcobalamin): Monitor (theoretical)
  • Cardiac metabolic enhancers (trimetazidine, ranolazine, leucovorin, creatine phosphate): Caution (within 30 days of intravenous NAD+)

Risk & Side Effects

  • High:
  • Medium:
  • Low: Acute Infusion-Related Gastrointestinal and Cardiorespiratory Distress; Serum High-Density Lipoprotein Cholesterol Reduction; Endotoxin Contamination and Pyrogenic Reactions from Improperly Compounded Injectables; Mild Oral Gastrointestinal and Nervous System Disturbances
  • Speculative: Tumorigenesis, Angiogenesis, and Senescence-Associated Secretory Phenotype Promotion; Methyl Donor Depletion and Vascular Pyridone Metabolite Accumulation

Monitoring

Marker Target Why
Whole-Blood or Plasma NAD+ No established target; tracked as change from individual baseline Efficacy marker: confirms biochemical target engagement from NAD+ therapy
HDL-C > 40 mg/dL in men; > 50 mg/dL in women (standard reference range) Safety check and marker expected to change: high-dose intravenous NAD+ lowered HDL-C by 5.80 mg/dL at 30 days
ALT & AST ALT: 7–56 U/L; AST: 8–33 U/L (standard reference range) Safety check: values > 3× the upper limit of normal stop or exclude NAD+ use
Serum Creatinine & eGFR Creatinine: 0.6–1.2 mg/dL; eGFR: ≥ 90 mL/min/1.73 m² (standard reference range) Safety check: serum creatinine ≥ 225 μmol/L (~2.55 mg/dL) stops or excludes intravenous NAD+
Plasma Homocysteine 5–15 μmol/L (standard reference range) Safety check: detects methyl-group depletion from nicotinamide N-methyltransferase (NNMT) clearance of high-dose NAD+, prompting methyl-donor adjustment
Resting Blood Pressure & Heart Rate Blood pressure: < 120/80 mmHg; Heart rate: 60–100 beats/min (standard reference range) Safety check and marker expected to change: excludes infusion at ≥ 180/110 mmHg and guides drip rate

Cadence: Baseline prior to starting therapy; blood pressure and heart rate before and continuously during each intravenous infusion; lipid, liver, kidney, and homocysteine panels rechecked at 1 week and 4 weeks after a loading course, and every 3–6 months during maintenance therapy.

Qualitative Assessment

  • Infusion tolerability: Absence of abdominal cramping, nausea, or chest pressure at the selected drip rate.
  • Physical stamina: Perceived improvements in daily energy and walking endurance over 4–12 weeks.
  • Sleep quality: Stable sleep onset and daytime cognitive clarity without evening overstimulation.